Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Feb;82(4):763–766. doi: 10.1054/bjoc.1999.0995

Analysis of radon-associated squamous cell carcinomas of the lung for ap53 gene hotspot mutation

Q Yang 1, H Wesch 1, K-M Mueller 2, H Bartsch 1, K Wegener 3, M Hollstein 1
PMCID: PMC2374385  PMID: 10732742

Abstract

Squamous cell lung carcinomas (SCC) from former employees of the Wismut uranium mining company (Saxony, Germany) were obtained from the Stollberg Archive in order to screen for p53 tumour suppressor gene codon 249 arg→met hotspot mutations, a putative molecular bio-dosimeter of alpha-particle (radon) exposure (Taylor et al (1994) Lancet343: 86–87; McDonald et al (1995) Cancer Epidemiol Biomarkers Prevent4: 791–793). Of the 29 archived samples of SCC meeting quality criteria for DNA analysis by polymerase chain reaction (PCR) and Hae III restriction enzyme digestion, two tumours were found that harboured this mutation. DNA sequencing confirmed the presence of a G to T base substitution within the Hae III site spanning codons 249 and 250 of the p53 gene that results in replacement of arginine (wild-type) by methionine at residue 249. When these data are combined with those from our previous study of tumours from the Stollberg Archive in which 50 lung tumours were examined, (including nine SCCs), we conclude that the G→T (arg→met) codon 249 mutation prevalence in the Wismut miner cohort is not sharply elevated in lung cancers in general (two mutations/79 tumours), or specifically in SCCs of the lung (two mutations/38 SCC) when compared to data from lung cancer patients with no reported occupational exposure to radon gas. © 2000 Cancer Research Campaign

Keywords: p53, alpha-particles, uranium, mutation

Full Text

The Full Text of this article is available as a PDF (79.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartsch H., Hollstein M., Mustonen R., Schmidt J., Spiethoff A., Wesch H., Wiethege T., Müller K. M. Screening for putative radon-specific p53 mutation hotspot in German uranium miners. Lancet. 1995 Jul 8;346(8967):121–121. doi: 10.1016/s0140-6736(95)92144-3. [DOI] [PubMed] [Google Scholar]
  2. Hainaut P., Hernandez T., Robinson A., Rodriguez-Tome P., Flores T., Hollstein M., Harris C. C., Montesano R. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res. 1998 Jan 1;26(1):205–213. doi: 10.1093/nar/26.1.205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Hei T. K., Bedford J., Waldren C. A. 53 mutation hotspot in radon-associated lung cancer. Lancet. 1994 May 7;343(8906):1158–1159. doi: 10.1016/s0140-6736(94)90262-3. [DOI] [PubMed] [Google Scholar]
  4. Hollstein M., Bartsch H., Wesch H., Kure E. H., Mustonen R., Mühlbauer K. R., Spiethoff A., Wegener K., Wiethege T., Müller K. M. p53 gene mutation analysis in tumors of patients exposed to alpha-particles. Carcinogenesis. 1997 Mar;18(3):511–516. doi: 10.1093/carcin/18.3.511. [DOI] [PubMed] [Google Scholar]
  5. Hollstein M., Rice K., Greenblatt M. S., Soussi T., Fuchs R., Sørlie T., Hovig E., Smith-Sørensen B., Montesano R., Harris C. C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1994 Sep;22(17):3551–3555. [PMC free article] [PubMed] [Google Scholar]
  6. Lo Y. M., Darby S., Noakes L., Whitley E., Silcocks P. B., Fleming K. A., Bell J. I. Screening for codon 249 p53 mutation in lung cancer associated with domestic radon exposure. Lancet. 1995 Jan 7;345(8941):60–60. doi: 10.1016/s0140-6736(95)91183-9. [DOI] [PubMed] [Google Scholar]
  7. McDonald J. W., Taylor J. A., Watson M. A., Saccomanno G., Devereux T. R. p53 and K-ras in radon-associated lung adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 1995 Oct-Nov;4(7):791–793. [PubMed] [Google Scholar]
  8. Schüttmann W. Schneeberg lung disease and uranium mining in the Saxon Ore Mountains (Erzgebirge). Am J Ind Med. 1993 Feb;23(2):355–368. doi: 10.1002/ajim.4700230212. [DOI] [PubMed] [Google Scholar]
  9. Sidransky D., Hollstein M. Clinical implications of the p53 gene. Annu Rev Med. 1996;47:285–301. doi: 10.1146/annurev.med.47.1.285. [DOI] [PubMed] [Google Scholar]
  10. Taylor J. A., Watson M. A., Devereux T. R., Michels R. Y., Saccomanno G., Anderson M. p53 mutation hotspot in radon-associated lung cancer. Lancet. 1994 Jan 8;343(8889):86–87. [PubMed] [Google Scholar]
  11. Venitt S., Biggs P. J. Radon, mycotoxins, p53, and uranium mining. Lancet. 1994 Mar 26;343(8900):795–795. doi: 10.1016/s0140-6736(94)91872-4. [DOI] [PubMed] [Google Scholar]
  12. Vähäkangas K. H., Samet J. M., Metcalf R. A., Welsh J. A., Bennett W. P., Lane D. P., Harris C. C. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet. 1992 Mar 7;339(8793):576–580. doi: 10.1016/0140-6736(92)90866-2. [DOI] [PubMed] [Google Scholar]
  13. Wu L. J., Randers-Pehrson G., Xu A., Waldren C. A., Geard C. R., Yu Z., Hei T. K. Targeted cytoplasmic irradiation with alpha particles induces mutations in mammalian cells. Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4959–4964. doi: 10.1073/pnas.96.9.4959. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES